U.S. tariffs on generics
Potential tariffs on pharmaceutical imports could impact margins; management is working with customers to ensure supply continuity but uncertainty remains.
DRREDDY / Q4-FY25 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
REVLIMID revenue cliff in January 2026
Exclusivity ends in January 2026, leading to significant revenue decline; management expects to offset through growth in other segments but risk remains.
Gross margin volatility from one-off costs
Q4 gross margin fell 300 bps due to manufacturing overhead and lower milestone income; while management considers it one-off, recurrence could pressure margins.
Semaglutide competition in Canada
Multiple players may launch generic semaglutide in Canada, leading to price erosion and lower-than-expected market share for Dr. Reddy's.